Cognitive
Cerebrolysin
Also called FPF-1070
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in roughly 40 countries.
The human evidence for Cerebrolysin used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Cerebrolysin at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 30–50 mg per administration
- How often
- Every day
- Where
- Intravenous (clinical setting)
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Cerebrolysin describe 30–50 mg per administration. Descriptive only, not a recommendation.
A porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids, not a single molecule, so no single elimination half-life describes it and none is modelled.
A porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids, not a single defined molecule. It is supplied as a sterile solution and dosed by volume — about 30–50 mL given intravenously once daily for 10–21 days, at roughly 215 mg of peptide per mL — not as a milligram amount, so the vial sizes and dose range shown here are nominal placeholders for a calculator that expects milligrams. The human evidence used the intravenous route, so no subcutaneous schedule is established and no schedule table is shown.
Where these numbers come from
- Heiss WD et al., Stroke 2012;43:630 (CASTA)Cerebrolysin 30 mL intravenously once daily for 10 days after acute ischemic stroke; the global outcome measure did not separate from placebo.